Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- ELISA drug discovery cytotoxicity toxicology non-human primates rhesus cynomolgus monkeys pharmacokinetics serum endogenous homology immunoglobulins species EIAs enzymes immunoassays kits measures measurements humans antibody antibodies IgG1 effectors Fc receptors leukocytes mediates antibody-induced cellular cells ADCC complement-mediated complements rodent plasma
- Product Overview:
Cayman’s Human Therapeutic IgG2 ELISA Kit is an immunometric (i.e. sandwich) assay that can be used for the quantification of human IgG2 in monkey or rodent plasma and serum without prior sample purification. The standard curve spans the range of 3.13-200 ng/ml, with a lower limit of quantification (LLOQ) of 3.13 ng/ml. The assay has been validated in serum from cynomolgus monkey, rhesus monkey, and rat. Although a human monoclonal IgG2 antibody is supplied as a standard, we acknowledge that minor differences in protein structure or post-translational modification may exist between our standard and the human IgG2 test article that is being assessed by the customer and that these differences could lead to inaccuracies in the quantification of the test article. Thus, we anticipate that many of our customers will prefer to use their own purified therapeutic monoclonal IgG2 as the standard in this ELISA. In that event, we recommend that the customer test their own standard in the ELISA at a similar dose range as the standard provided in the kit.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.